INDP
Indaptus Therapeutics, Inc. NASDAQ$2.15
Mkt Cap $3.8M
52w Low $1.51
3.5% of range
52w High $19.91
50d MA $2.20
200d MA $3.46
P/E (TTM)
-0.1x
EV/EBITDA
0.3x
P/B
0.7x
Debt/Equity
0.0x
ROE
-661.5%
P/FCF
-0.2x
RSI (14)
—
ATR (14)
—
Beta
0.99
50d MA
$2.20
200d MA
$3.46
Avg Volume
50.5K
About
Indaptus Therapeutics, Inc., a pre-clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical oncology candidate is Decoy20 to single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as hepatitis B virus and human immunodeficiency virus infection, whic…
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 17, 2026 | AMC | -4.36 | -3.10 | +28.9% | 1.96 | +1.5% | -4.6% | -10.2% | -13.3% | -11.7% | -13.3% | — |
| Nov 12, 2025 | AMC | -4.17 | -2.98 | +28.5% | 2.89 | -2.8% | +2.4% | -13.1% | -21.5% | -20.1% | -28.4% | — |
| Aug 13, 2025 | AMC | -9.24 | -9.09 | +1.6% | 8.44 | -5.8% | -7.5% | -15.6% | -8.1% | -12.0% | -12.1% | — |
| May 14, 2025 | AMC | -11.48 | -8.96 | +22.0% | 11.86 | -0.8% | -0.8% | +6.0% | -7.9% | -6.7% | -10.3% | — |
| Mar 13, 2025 | AMC | -0.41 | -0.38 | +7.3% | 22.59 | +1.3% | -0.2% | +0.7% | +0.4% | -4.5% | -6.4% | — |
| Nov 12, 2024 | AMC | -0.47 | -0.32 | +31.9% | 32.20 | +0.0% | +2.6% | -1.7% | -3.5% | -4.3% | -10.4% | — |
| Aug 12, 2024 | AMC | -0.54 | -0.47 | +13.0% | 47.88 | -0.6% | -2.3% | -1.8% | -2.3% | -3.5% | -4.1% | — |
| May 8, 2024 | AMC | -0.57 | -0.45 | +21.1% | 57.96 | +1.0% | +1.0% | +3.9% | +2.4% | +2.9% | +9.7% | — |
| Mar 13, 2024 | AMC | -0.54 | -0.47 | +13.0% | 56.00 | -3.0% | -4.5% | -6.5% | -3.5% | +2.5% | +16.0% | — |
| Nov 6, 2023 | AMC | -0.55 | -0.47 | +14.5% | 75.04 | +6.0% | -10.1% | -4.1% | -14.4% | -13.1% | -17.2% | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nov 13 | Maxim Group | Maintains | Buy → Buy | — | $32.20 | $32.20 | +0.0% | +2.6% | -1.7% | -3.5% | -4.3% | -10.4% |
| Oct 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $35.56 | $37.24 | +4.7% | +12.6% | +22.0% | +18.9% | +15.7% | +50.4% |
| Jun 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $69.16 | $68.60 | -0.8% | +6.9% | +0.8% | -6.1% | -8.9% | -10.1% |
| Apr 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $77.56 | $82.60 | +6.5% | -5.4% | +0.7% | -4.0% | -9.0% | -14.8% |
| Sep 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $110.60 | $111.16 | +0.5% | -11.4% | -15.7% | -31.4% | -37.0% | -29.6% |
| Aug 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $69.44 | $70.00 | +0.8% | -9.7% | -12.5% | -3.6% | -2.0% | -2.0% |
| Aug 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $61.88 | $61.32 | -0.9% | +4.1% | +12.2% | +1.4% | -1.8% | +8.1% |
| Aug 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $51.80 | $48.72 | -5.9% | -3.2% | -2.7% | +19.5% | +24.3% | +34.1% |
| May 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $73.08 | $73.64 | +0.8% | -4.6% | -5.4% | -7.7% | -22.6% | -17.6% |
| Mar 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $45.36 | $47.04 | +3.7% | +3.7% | +0.0% | +3.1% | +11.7% | +17.3% |
Recent Filings
8-K · 5.02
!!! Very High
Indaptus Therapeutics, Inc. -- 8-K 5.02: Executive Change
Indaptus Therapeutics (INDP) strengthens its board governance by appointing Tim Ruan as an independent director, effective April 22, 2026, potentially enhancing oversight and strategic guidance.
Apr 24
8-K · 5.02
!!! Very High
Indaptus Therapeutics, Inc. -- 8-K 5.02: Executive Change
Indaptus Therapeutics appointed Tim Ruan as an independent director effective April 22, 2026, strengthening board governance and oversight of the biopharmaceutical company's operations.
Apr 23
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
INDP appointed a new CFO, signaling potential strategic shifts in financial management that could affect capital allocation, investor communications, and operational efficiency going forward.
Apr 3
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
Avraham Ben-Tzvi's appointment to lead the Nominating Committee signals potential governance changes and future board composition shifts that could influence INDP's strategic direction and executive leadership.
Mar 24
8-K · 5.03
! Medium
Indaptus Therapeutics, Inc. -- 8-K 5.03: Amendment to Articles / Bylaws
Indaptus Therapeutics increased authorized common shares to 1 billion and enabled written consent voting, providing greater capital-raising flexibility and streamlined governance for future transactions.
Feb 27
8-K · 1.01
! Medium
Indaptus Therapeutics, Inc. -- 8-K 1.01: Governance / Corporate
Indaptus Therapeutics secured voting commitments from major shareholders in exchange for reducing warrant exercise prices, consolidating control ahead of a February 26, 2026 shareholder meeting.
Feb 12
Data updated apr 25, 2026 3:33pm
· Source: massive.com